MoonLake Immunotherapeutics - Class A MLTX

NAS: MLTX | ISIN: KY61559X1045   17/05/2024
39,75 USD (-2,72%)
(-2,72%)   17/05/2024

16 mei 2024 · MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa · Persbericht

10 maart 2024 · MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day · Persbericht

4 maart 2024 · MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 · Persbericht

29 februari 2024 · MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 · Persbericht

26 februari 2024 · MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) · Persbericht

14 november 2023 · MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update · Persbericht

5 november 2023 · MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis · Persbericht

15 oktober 2023 · MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa · Persbericht

11 oktober 2023 · MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress · Persbericht

6 september 2023 · MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 · Persbericht

10 augustus 2023 · MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update · Persbericht

25 juli 2023 · MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts   · Persbericht

28 juni 2023 · MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares · Persbericht

26 juni 2023 · MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering · Persbericht

25 juni 2023 · MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa · Persbericht

12 mei 2023 · MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update · Persbericht

3 mei 2023 · MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply · Persbericht

19 april 2023 · MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today · Persbericht

20 maart 2023 · MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update · Persbericht

2 februari 2023 · MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa · Persbericht

Mijn selecties